摘要
Chimeric antigen receptor(CAR)is a synthetic antigen receptor containing a specific antigen-recognition ectodomain to make T cells selectively attack cancer cells,a hinge-transmembrane region to confer stable surface expression,and one or more intracellular signaling domains to regulate T-cell activation.CAR T-cell therapy has produced unprecedented clinical outcomes for treating cancers,particularly B-cell malignancies.However,increasing clinic data reveal some limitations of current CAR T therapies.For example,>30%of B-cell malignancy patients who initially achieved complete remission encountered relapses after 1-year infusion of CAR T cells.In case of solid tumors,most of the patients did not benefit from CAR T treatment(Park et al.,2018;Schmidts and Maus,2018).CAR T-cell persistence,defined as how long CAR T cells could survive in vivo after infusion into patients,is one of the major factors affecting the clinical outcomes of CAR T therapy(Porter et al.,2015).Therefore,it is important to understand the molecular mechanism(s)controlling the persistence of CAR T cells.
基金
The described work was supported by grants from the National Key R&D Program of China(2019YFA0111001 to H.W.)
the National Natural Science Foundation of China(31670919 to H.W.).
